Gilead Sciences, Inc. Share Price and Company Fundamentals
Last traded: Today at 8:00 PM
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Key Metrics
PE ratio
17.43
PB ratio
4.53
Dividend yield
3.88%
Beta
0.41
Market cap
$89.26B
Enterprise value
$113.22B
Company profile
| Industry / Sector | Drug Manufacturers—General / Healthcare |
|---|---|
| Full time employees | 13600 |
| Website | http://www.gilead.com |
| Mailing address | 333 Lakeside Drive Foster City CA 94404 United States |
| Phone / Fax | 650 574 3000 / 650 578 9264 |
Dividends
Dividend yield
3.88%
Dividend amount
$2.78
Payout ratio
67.80%
5Y Avg. yield
3.36%
Gilead Sciences, Inc. paid $2.78 dividend and the ex-dividend date was 13 Sept 2021.The dividend payout ratio is 67.80%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GILD dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
GILD's forward dividend amount is $2.84 and the forward dividend yield is 3.96%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Sep 2021, following are the company executives and directors listed on Gilead Sciences, Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO | 56 | 7.48M |
| Mr. Andrew D. Dickinson | Exec. VP & CFO | 50 | 2.71M |
| Mr. Brett A. Pletcher | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. | 52 | 2.71M |
| Ms. Johanna Mercier | Chief Commercial Officer | 50 | 4.86M |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 57 | 3.85M |
| Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer | 58 | |
| Ms. Jacquie Ross C.F.A. | VP of Investor Relations | ||
| Ms. Jyoti K. Mehra | Exec. VP of HR | ||
| Dr. Taiyin Yang | Exec. VP of Pharmaceutical Devel. & Manufacturing | 66 | |
| Dr. Diana M. Brainard M.D. | Sr. VP of HIV & Emerging Viral Infections | 49 |
Profitability and management effectiveness
Profit margin
19.38%
Operating margin
46.82%
Return on assets
12.58%
Return on equity
27.14%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Gilead Sciences, Inc. is 89.26B and its enterprise value is 113.22B. The enterprise value to revenue ratio of GILD is 4.25.
The GILD's stocks Beta value is 0.41 making it 59% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Gilead Sciences, Inc. (NASDAQ:GILD) Frequently Asked Questions
1. What is Gilead Sciences, Inc.'s Stock Symbol?
Gilead Sciences, Inc. trades on NASDAQ under the ticker symbol "GILD".
2. What is Gilead Sciences, Inc.'s stock price today?
One share of GILD stock can currently be purchased for approximately $71.19.
3. How can I contact Gilead Sciences, Inc.?
Gilead Sciences, Inc.'s mailing address is 333 Lakeside Drive Foster City CA 94404 United States. The company can be reached via phone at 650 574 3000.
4. What is Gilead Sciences, Inc.'s official website?
The official website of Gilead Sciences, Inc. is http://www.gilead.com.